Qian Chu clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   ACHELOUS · Cadonilimab (AK104) Plus Chemotherapy as First-line…ACHELOUS · Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) · Programmed Cell Death Ligand 1 (PD-L1) Negative

   Enrollment closed, study ongoing

   Qian Chu·Phase 2· NCT06001151· Registry history of NCT06001151 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Minor

   CAPSTONE · Camrelizumab Plus Famitinib as Treatment · Advanced or…CAPSTONE · Camrelizumab Plus Famitinib as Treatment · Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

   Trial status changed: Unknown → Completed

   Also in this update: Final enrollment: 17 participants (planned 28); and 1 more change in the last 30 days

   Qian Chu·Phase 2· NCT04888429· Registry history of NCT04888429 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.